News

Grant History

The $5.1M of total grant support we've given to funding research is made possible by the generosity of our sponsors and donors. Real people making an impact on saving children's eyesight.

Grant Amount

$3M

2024

$2.1M

2025

Year

Grant Amount

Month

Amount/ month

Purpose

2026

$1.1M

January

$1.1M

To close the remaining funding gap required to launch the AXV-101 clinical trial, enabling the study to begin in early 2026.

2025

$1M

September

$1M

To support clinical development of the first-in-human trial, including trial preparation and regulatory progress following clinical trial clearance.

2024

$3M

October

$1M

December

$2M

To fund the preclinical development and regulatory preparation of AXV-101, a gene therapy for Bardet-Biedl Syndrome type 1 (BBS1), advancing the program toward its first human clinical trial.